secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lucid Diagnostics Inc. (LUCD)
CIK:        0001799011
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001493152-24-019020
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lucid Diagnostics Q1 revenue $1.0M; net loss $18.1M; EsoGuard volume up 10% sequentially
--------------------------------------------------------------------------------

- EsoGuard revenue $1.0M, flat vs Q4'23 but up 124% YoY.
- GAAP net loss $18.1M ($0.40/share); non-GAAP adjusted loss $9.4M ($0.21/share).
- Cash $24.8M at quarter end; subsequent $11.6M from Series B-1 offering.
- MolDX pre-submission meeting scheduled July 17, 2024 for EsoGuard coverage.
- EsoGuard test volume 2,420, +10% sequentially and +31% YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799011/000149315224019020/0001493152-24-019020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799011/000149315224019020/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-019020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer